Abstract

Multiple myeloma (MM) is a hematologic malignancy of differentiated plasma cells that accumulates and proliferates in the bone marrow. MM patients often develop bone disease that results in severe bone pain, osteolytic lesions, and pathologic fractures. These skeletal complications have not only a negative impact on quality of life but also a possible effect in overall survival. MM osteolytic bone lesions arise from the altered bone remodeling due to both increased osteoclast activation and decreased osteoblast differentiation. A dysregulated production of numerous cytokines that can contribute to the uncoupling of bone cell activity is well documented in the bone marrow microenvironment of MM patients. These molecules are produced not only by malignant plasma cells, that directly contribute to MM bone disease, but also by bone, immune, and stromal cells interacting with each other in the bone microenvironment. This review focuses on the current knowledge of MM bone disease biology, with particular regard on the role of bone and immune cells in producing cytokines critical for malignant plasma cell proliferation as well as in osteolysis development. Therefore, the understanding of MM pathogenesis could be useful to the discovery of novel agents that will be able to both restore bone remodelling and reduce tumor burden.

Highlights

  • Multiple myeloma (MM) is a hematologic malignancy characterized by the accumulation of monoclonal plasma cells in the bone marrow (BM) [1], the presence of monoclonal immunoglobulin (Ig) in the serum or urine, osteolytic bone lesions, renal disease, and immunodeficiency

  • This review focuses on the current knowledge of MM bone disease biology, with particular regard on the role of bone and immune cells in producing cytokines critical for malignant plasma cell proliferation as well as in osteolysis development

  • We demonstrated that decoy receptor 3 (DcR3), a member of the TNF receptor superfamily and known to be involved in OC differentiation [17], was overexpressed by malignant plasma cells and T-lymphocytes obtained from MM patients with osteolysis [18, 19]

Read more

Summary

Introduction

Multiple myeloma (MM) is a hematologic malignancy characterized by the accumulation of monoclonal plasma cells (over 10% by definition) in the bone marrow (BM) [1], the presence of monoclonal immunoglobulin (Ig) in the serum or urine, osteolytic bone lesions, renal disease, and immunodeficiency. It is mainly a disease of old patients, with a median age at diagnosis of 65–70 years. We discuss the pathogenesis of MM bone disease and focus on advances in our understanding of its biology, Clinical and Developmental Immunology with particular regard on the role of bone and immune cells in producing cytokines critical for the induction of osteolysis development in MM

The Biology of MM Bone Disease
MM Cells
Osteocytes
T-Lymphocytes
10. Novel Antimyeloma-Related Bone Disease Drugs
Findings
11. Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call